Hepatitis B treatment, Baraclude’s drug price cut from the 7th
From the 7th, the upper health insurance benefit of the BMS Pharmaceutical Korea’s(CEO Hye-sun Park) chronic hepatitis B treatment, Baraclude(generic name: entecavir), will be lowered to 53.55% of the original price before the patent expiration.
The drug price cut is followed by the Ministry of ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
